Chair: Christopher M. O'Connor

10:00 AM
Welcome and Introduction
Christopher M. O'Connor

10:05 AM
Management of Chronic Heart Failure: What are the Opportunities for Improvement?
Barry H. Greenberg

Learning Objective: Become familiar with unmet needs in the chronic management of patients with heart failure

10:25 AM
Management of Acute Decompensated Heart Failure: How Can We Do Better?
G. Michael Felker

Learning Objective: Recognize the opportunities for improvement in the acute management of patients with heart failure

10:45 AM
New Therapeutic Approaches in Heart Failure John GF Cleland

Learning Objective: Evaluate clinical potential of novel therapeutic modalities for acute and long-term management of patients with heart failure

11:10 AM
Assessing the Clinical Value of Surrogate Endpoints in Heart Failure: A Point-Counterpoint Discussion

Pro Argument: Jay N. Cohn
Con Argument: Christopher M. O’Connor

Learning Objective: Assess clinical value of surrogate endpoints in trials of therapies for heart failure and their relevance for treatment selection

11:45 AM
Audience Q & A
Faculty

11:55 AM
Concluding Remarks
Christopher M. O’Connor

Supported by an educational grant from Cytokinetics.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Barry M. Massie

10:00 AM
Welcome and Overview
Barry M. Massie

Learning Objective: Define the impact of atrial fibrillation in patients with heart failure 10:05 AM
Impact of Atrial Fibrillation on the Heart Failure Patient
Lynne Warner Stevenson

Learning Objective: Describe results of recent trials evaluating pharmacologic intervention for atrial fibrillation

10:30 AM
Rate and Rhythm Control: Update on New Medical Options and Interventions in Atrial Fibrillation
Gerald V. Naccarelli

Learning Objective: Describe the role of atrial fibrillation ablation in the heart failure patient

10:55 AM
Anticoagulation Therapies: Present and Future
Michael D. Ezekowitz

Learning Objective: Describe the results of recent trials evaluating newest anticoagulation therapies and study designs on ongoing trials

11:20 AM
Question fronm the Audience
Faculty

11:30 AM
Managing the Patient with Heart Failure and Atrial Fibrillation (case presentation)
Barry M. Massie

Learning Objective: Outline a case-based approach to improve current treatment standards for patients with atrial fibrillation and heart failure

11:55 AM
Summary and Closing Remarks
Barry M. Massie

Supported by an educational grant from sanofi-aventis.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Clyde W. Yancy

1:00 PM
Welcome and Introduction
Clyde W. Yancy

1:05 PM
2008 Definition of Quality
Eric. D. Peterson

Learning Objective: What practices define quality in healthcare?

1:25 PM
Contemporary Heart Failure Care: Are Evidence-Based Therapies Being Consistently Provided?
Gregg C. Fonarow

Learning Objective: Define the important treatment gaps in heart failure; discuss the challenges of defining and improving quality in the outpatient chronic care setting

1:55 PM
Addressing and Overcoming Disparities in Heart Failure Care
Adrian F. Hernandez

Learning Objective: Address quality of care in special populations and disparities in care of novel measures as a function of race and gender

2:20 PM
Guidelines, Performance Measures and Core Measures: What do You Need to Know and Why?
Ileana L. Piña

Learning Objective: Identify the difference between the several quality metrics

2:45 PM
Panel Discussion with Written Q & A
Faculty

Supported by an educational grant from Medtronic, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: William T. Abraham

1:00 PM
Introduction
William T. Abraham

1:05 PM
Pitfalls and Promises: A History of Beta-Blockers in Heart Failure
Douglas Mann

Learning Objective: Describe the results of landmark clinical trials of beta-blockers in heart failure and potential reasons for variability in study outcomes

1:25 PM
Genetic Influences on Disease Severity and Treatment Resistance in Heart Failure
William T. Abraham

Learning Objective: Identify genetic factors that may significantly influence responses to treatment in patients with heart failure

1:45 PM
Panel Discussion with Audience Response
Faculty

2:00 PM
Influences of Alpha- and Beta-adrenoceptor Polymorphisms on Response to Beta-blocker Treatment in Patients with Heart Failure
Michael R. Bristow

Learning Objective: Describe the influence of selected adrenoceptor polymorphisms on the efficacy of beta-blockers in the treatment of heart failure

2:20 PM
Using Genetic Information to Select Treatment for Patients with Heart Failure
Christopher M. O'Connor

Learning Objective: Summarize new information about genetic determinants of responses to beta-blockers in heart failure

2:40 PM
Panel Discussion with Audience Response
Faculty

Supported by an educational grant from ARCA biopharma.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Gary S. Francis

1:00 PM
Welcome and Introduction
Gary S. Francis

1:05 PM
Defining the Cardiorenal Syndrome in ADHF: A 2008 Perspective
Michael M. Givertz

Learning Objective: Describe the multidimensional nature of ADHF and its association with renal dysfunction

1:30 PM
Keys to Success: How the Pathophysiology of the Cardiorenal Syndrome in ADHF Impacts Treatment
Andrew J. Boyle

Learning Objective: Summarize the challenges in selecting therapies for the management of ADHF

1:55 PM
Improving Patient Outcome: Changing the Face of Treatment of the Cardiorenal Syndrome in ADHF
Barry M. Massie

Learning Objective: Evaluate the impact of long-term renal function and mortality associated with various pharmacologic interventions used in ADHF

2:20 PM
Science in Action: A Clinical Case Review
Andrew J. Boyle, Gary S. Francis, Michael M. Givertz, Barry M. Massie, W.H. Wilson Tang

Learning Objective: Consider safety and efficacy data for current ADHF therapies when selecting appropriate therapy

2:45 PM
Questions and Answers
Faculty

2:55 PM
Closing Remarks
Gary S. Francis

Supported by an educational grant from Merck.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Walter J. Koch
                   Howard A. Rockman

3:15 PM^*
The 2^nd Distinguished Lecture in Basic Science

Nitric Oxide as a Unique Signaling Molecule in Physiology
Louis J. Ignarro

4:00 PM^*
Molecular Mechanisms of Cardiomyopathy
Jonathan G. Seidman, Jr.

4:30 PM^*
Calcium Regulation in Heart Failure
Donald M. Bers

5:00 PM^*
Hypertension and Vascular Dysfunction: Role of Nitric Oxide
Michael E. Mendelsohn

5:30 PM^*
Rho-Mediated Signaling to Cardiomyocyte Apoptosis and Protection
Joan Heller Brown



^* 25 minute presentation, 5 minute audience questions

Chair: James B. Young

4:00 PM
Setting the Stage
James B. Young

4:10 PM
Three Generations of Beta-Blockers in Heart Failure: A Clinical Review
Mark E. Dunlap

Learning Objective: Classify the various beta-blockers to differences in their beta-adrenergic receptor selectivity

4:30 PM
Mechanisms of Beta-Blocker Action I: Reverse Remodeling and Antiarrhythmic and Hemodynamic Effects
Michael R. Bristow

Learning Objective: Analyze the results of pivotal studies that support the use of beta-blockers in patients with HF

4:50 PM
Mechanisms of Beta-Blocker Action II: Vasodilating and Antioxidant Activity
Jay N. Cohn

Learning Objective: Describe the two principal mechanisms of vasodilation in beta-blockers: alpha-adrenergic blockade and increased nitric oxide availability

5:10 PM
Safety and Tolerability of Beta-Blockers in Heart Failure: A Comparative Review
Philip A.Poole-Wilson

Learning Objective: Compare the relative safety and tolerability of the various beta-blockers

5:30 PM
Question-and-Answer Session

Supported by an educational grant from Forest Pharmaceuticals, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Clyde W. Yancy

4:00 PM
Introduction and Overview
Clyde W. Yancy

4:05 PM
2005 ACC/AHA and Focused Update
Mariell L. Jessup

Learning Objective: List key practice guidelines regarding the use of devices in the care of patients with heart failure, how they differ from other guidelines, and why

4:25 PM
2006 HFSA Comprehensive Heart Failure Practice Guidelines
Invited

Learning Objective: List key practice guidelines regarding the use of devices in the care of patients with heart failure, how they differ from other guidelines, and why

4:45 PM
2006 ACC/AHA/ESC SCD/VA Guidelines
Leslie A. Saxon

Learning Objective: List key practice guidelines regarding the use of devices in the care of patients with heart failure, how they differ from other guidelines, and why

5:05 PM
2008 ACC/AHA Device Guidelines
William G. Stevenson

Learning Objective: List key practice guidelines regarding the use of devices in the care of patients with heart failure, how they differ from other guidelines, and why

5:25 PM
Case-Based Panel Discussion
Clyde W. Yancy

Learning Objective: Use available recommendations to guide decisions regarding the potential use of devices in the care of patients with heart failure

Supported by an educational grant from Boston Scientific Corporation.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: James B. Udelson

4:00 PM
Welcome and Introduction
James B. Udelson

Learning Objective: Understand the typical clinical characteristics and outcomes of ADHF patients

4:10 PM
Hyponatremia in Decompensated HF
Steven R. Goldsmith

4:20 PM
Case I: 65 year old hyponatremic male

Learning Objective: Improve treatment for the ADHF patient with hyponatremia

4:40 PM
Renal Dysfunction in Decompensated Heart Failure
Douglas L. Mann

4:50 PM
Case II: 72 year old male, previous HF, renal dysfunction

Learning Objective: Improve treatment for the ADHF patient with renal dysfunction

5:10 PM
Hypertension and Hypotension in Decompensated HF
Barry H. Greenberg

5:20 PM
Case III: 78 year old female, previous HF, hypotensive

Learning Objective: Optimize treatment for the high risk ADHF patient

5:40 PM
The Case for New Heart Failure Therapies
James E. Udelson

Learning Objective: Critically assess recent clinical trails of new pharmacologic interventions for the management of ADHF

5:50 PM
Final Discussion and Q & A
Faculty

Supported by an educational grant from Otsuka America Pharmaceuticals.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: William T. Abraham

7:00 AM
Introduction
William T. Abraham

7:05 AM
Maximizing the Patient Benefit from CRT Therapy
Ayesha Hasan

Learning Objective: Describe how measurement of dyssynchrony and patient selection can improve the effective use of CRT in patients with heart failure

7:25 AM
Using Monitoring Devices to Optimize Patient Care
Philip B. Adamson

Learning Objective: Where feasible, use approved monitoring devices to improve care of the patient with heart failure

7:45 AM
Panel Discussion
Faculty

Supported by an educational grant from St. Jude Medical, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Dominic Sica

7:00 AM
Welcome and Scope of the Problem
Dominic Sica

Learning Objective: Describe the extent and nature of hyponatremia in heart failure

7:15 AM
Diagnosis and Conventional Treatment of Hyponatremia: Opportunities for Improvement
Moderator: Dominic Sica
Discussant: Jalal Ghali

Learning Objectives: Effectively recognize and confirm the diagnosis of hyponatremia in heart failure patients; describe the advantages, disadvantages, and places in therapy of conventional treatment to modalities for hyponatremia

7:30 AM
New Treatment Options for Hyponatremia: Focus on AVP Receptor Antagonists

Moderator: Dominic Sica
Discussant: Jalal GhaliI

Learning Objectives: Describe the pharmacology, efficacy, safety and potential place in therapy of the new class of vasopressin antagonists with respect to treatment of hyponatremia in heart failure patients; implement strategies for treatment of hyponatremia in CHF patients that will maximize clinical efficacy and patient outcomes

7:45 AM
Discussion, Questions and Answers
Faculty

Supported by an educational grant from Biogen Idec.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Jay N. Cohn
                  Arnold M. Katz

8:30 AM
Presidential Address
Barry H. Greenberg

8:45 AM
Metabolic Syndrome: A Detriment to Societal Evolution
Salim Yusuf

9:10 AM
Tackling the Obesity Epidemic Through Urban Planning
Richard J. Jackson

9:35 AM
Particulate Matter Air Pollution and Heart Health
Joel D. Kaufman

Moderators: Gary S. Francis
                   TBN

10:30 AM^*
DIPTA - A thyroid Hormone Analog to Treat Heart Failure: Phase II Trial VA Cooperative Study
Steven Goldman
Commentary: Gary S. Francis

10:52 AM^*
Predictors of Clinical Success to Continuous Aortic Flow Augmentation in Heart Failure Exacerbation Refractory to Pharmacological Therapy: Analysis of the Multicenter MOMENTUM Trial
Mandeep R. Mehra
Commentary: Clyde W. Yancy

11:14 AM^*
Results of a Multicenter, Randomized, Double-Blind, Double-Dummy, ParallelGroup Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular and Systolic Volume Index in subjects with Stable Chronic Heart Failure (The COMPARE Trial)
Barry H. Greenberg
Commentary: Gregg C. Fonarow

11:36 AM^*
Safety and Efficacy of Sertraline for Depression in Patients with Congestive Heart Failure (SADHART-CHF)
Christopher M. O’Connor
Commentary: Douglas L. Mann

^* 22 minutes allotted: 15 minute presentation, 8 minute commentary

Moderators: Sharon A. Hunt
                   James B. Young

10:30 AM
Ventricular Interdependence in Decompensated Heart Failure
Gary E. Newton

10:50 AM
The Stiff Heart: Distinguishing Restriction from Constriction
Kanu Chatterjee

11:10 AM
Nuclear Images in Heart Failure
Vasken Dilsizian

11:30 AM
Histological Pearls in Heart Failure
Marc K. Halushka

11:50 AM
Panel Discussion

Moderators: Nancy M. Albert
                   Sandra B. Dunbar

10:30 AM^*
The Relationship Among Depressive Symptoms, N-pro B Type Natriuretic Peptide, and Cardiac Events in Patients with Heart Failure
Eun Kyeung Song

10:48 AM^*
Living with Advanced Heart Failure: The Patient Experience
Bonita L. Huiskes

11:06 AM^*
Factors Influencing Health Status Among Thai Patients with Heart Failure
Chennet Phonphet

11:24 AM^*
Montreal Cognitive Assessment may be an Appropriate Tool to Assess Cognitive Dysfunction In Heart Failure
Ponrathi R. Athilingam

11:42 AM^*
The Advantages and Disadvantages of Heart Failure Disease Management when Randomly Assigned to be Delivered by Telehealth or Telephone
Kathryn H. Bowles

^* 10 minute abstract presentation, 8 minute discussion

Moderators: Wilson S. Colucci
                   Bodh Jugdutt

10:30 AM^*
New Insights into the Effect of Mineralocorticoids on Circulating Progenitor Cell Counts in Canine Models of Cardiovascular Disease: The Case of Accelerated Senescence
Barry A.Boilson

10:48 AM^*
Alpha-1 Adrenergic Receptor Subtypes in Human Heart Failure
Brian C. Jensen

11:06 AM^*
CYP3A5*1/*3 Genetic Polymorphism is Associated with Post Cardiac Transplant Renal Dysfunction in Patients Treated with Calcineurin Inhibitors
Simon de Denus

11:24 AM^*
Engineered Mutation of Human B-Type Natriuretic Peptide to Preserve Renal Perfusion Pressure
Candace YW Lee

11:42 AM^*
Prediction of Recovery in Heart Failure with Genomic Biomarkers
Bettina Heidecker

^* 10 minute presentation, 8 minute discussion

Moderators: Peipei Ping
                  Mark A. Sussman

10:30 AM^*
GLP-1(7-36) and GLP-1(9-36) Protect Murine Hearts from Post-Ischemic Contractile Dysfunction
Christopher P. Kolibash

10:48 AM^*
Mast Cells, the Allergic Responders, A Target of Heart Failure Therapy?
Suresh S.Palaniyandi

11:06 AM^*
Adoptive Transfer of Regulatory T Cells Protects Against Coxsackievirus-induced Myocarditis
Yu Shi

11:24 AM^*
Cardiac-Specific Overexpression of a Dominant Negative (DN) p67^phox Mutant Shows Reduction in Mouse Heart Size
Qiong Zhao

11:42 AM^*
The Mechanism of Cardiac Failure in Experimental Myocardial Infarction
Nicholas T. Befera

^* 10 minute presentation, 8 minute discussion

1. Following the Heart Failure Patient: Prognostic Scores, QOL, BNP?
   James L. Januzzi, Wayne C. Levy, John A. Spertus



2. How to Facilitate Patient-Provider Communication in Heart Failure
   Paul J. Hauptman, Corrine Y. Jurgens, Mark D. Sullivan



3. How to Deal with "Remote Monitoring" of Devices
   Philip B. Adamson, Robert C. Bourge, Robin J. Trupp



4. How to Manage Behavior, Emotions, and Depression in Heart Failure
   Susan J. Ammon, Debra K. Moser, Christopher M. O'Connor



5. How to Foster Evidence-Based Practice in a Busy Cardiology Practice
   Marie Galvao, John Golden, Mary N. Walsh



6. Heart Failure Images: Vortices, Mitochondrial Alterations, Neuronal Imaging
   James Caldwell, Bijoy Khandheria, Jagat Narula

Moderators: Steven R. Goldsmith
                  W.H. Wilson Tang

12:30 PM^*
How Often Does Cardiotoxicity Lead to Discontinuation of Trastuzumab?
Gregory R. Hartlage

12:45 PM^*
Features and Hospital Outcomes for Nonadherent Patients with Heart Failure: Findings from GWTG-HF
Amrut V. Ambardekar

1:00 PM^*
Weekend Hospital Admission for Heart Failure: Influence on Quality of Care, Length of Stay, and In-Hospital Mortality
Gregg C. Fonarow

1:15 PM^*
Can the Seattle Heart Failure Model Be Used to Risk Stratify Patients For an LVAD: Application to REMATCH Patients
Wayne C. Levy

^* 10 minute presentation, 5 minute audience discussion

Moderators: Daniel Burkhoff
                   Clyde W. Yancy

2:00 PM
Gene Therapy Based Intervention - SERCA2A
Roger J. Hajjar

2:20 PM
Nitric Oxide Scanverage in Cardiogenic Shock
Frank W. Smart

2:40 PM
Pressure Sensors: Which One and For What Condition
Phillip B. Adamson

3:00 PM
A Device for Diastolic Heart Failure: Myth or Possibility
Michael R. Zile

3:20 PM
Panel Discussion

Moderators: Ayan R. Patel
                  James E. Udelson

2:00 PM
Genetics of HCM
Luisa Mestroni

2:20 PM
Clinical Decision Trees in HCM: Risk of Sudden Death
Harry Rakowski

2:40 PM
Contemporary Update on Alcohol Septal Ablation
William H. Spencer, III

3:00 PM
Athletes and Sudden Death Syndromes
Mark S. Link

3:20 PM
Panel Discussion

Moderators: Lili A. Barouch
                   Gary D. Lopaschuk

2:00 PM
Basic Mechanisms of Adipokines: Leptin, Adiponectins and Beyond
Kenneth Walsh

2:20 PM
Glucagon-Like Peptide-1 as a Treatment of Heart Failure
Richard P. Shannon

2:40 PM
Insights From Animal Models to Human Obesity
E. Dale Abel

3:00 PM
Omega-3 Polyunsaturated Fatty Acids and Heart Failure
William C. Stanley

3:20 PM
Panel Discussion

Moderators: Sanjiv M. Narayan
                   John D. Parker

2:00 PM
Heart Failure and Ventricular Arrhythmias: Clinical Observations
Alfred E. Buxton

2:20 PM
What Mechanisms Link Heart Failure with Arrhythmias: Genes, Calcium, Stretch or Other Factors
Stanley Nattel

2:40 PM
Risk Stratifiers in Addition to Ejection Fraction: State of the Art 2008
William G. Stevenson

3:00 PM
When Should We NOT Put an ICD in Heart Failure Patients
Michael W. Rich

3:20 PM
Panel Discussion

Moderators: Paul B. Rosenberg
                   Yibin Wang

2:00 PM^*
Consequences of Dyssynchrony and Resynchronization
David A. Kass

2:22 PM^*
The Integin/Talin/Vinculim Axis and the Myocardium
Robert S. Ross

2:44 PM^*
Pinch Function in the Heart
Ju Chen

3:07 PM^*
Integrin Linked Kinase and the Heart
Gregory E. Hannigan

^* 20 minute presentation, 2-3 minute audience discussion

Judges: Gary S. Francis
                   Barry H. Greenberg
                   Marvin A. Konstam

4:00 PM - Opening Remarks
Judge Marvin A. Konstam Presiding

4:05 PM - Case I: Appeal Against: Weight Reduction is Beneficial in Heart Failure Patients

Brought by: Stefan D. Anker
Countered by: Carl V. Leier

(15 minutes for each to present)

4:35 PM - Questions from the Judges
4:45 PM - Judgement Rendered

4:45 PM - Case II: Appeal Against: Mouse Research Drives Translation into Humans

Brought by: Jay N. Cohn
Countered by: Arthur M. Feldman

(15 minutes for each to present)

5:15 PM - Questions from the Judges
5:25 PM - Judgement Rendered

5:30 PM - Court Adjourned

Moderators: John P. Boehmer
                   David S. Feldman

4:00 PM
Beta Blockers and Reverse Remodeling
Mark H. Drazner

4:20 PM
Aldosterone Antagonists and Reverse Remodeling
James E. Udelson

4:40 PM
Electrical Therapies for HF: CRT and CCM
William T. Abraham

5:00 PM
Hemodynamic Unloading and Reverse Remodeling
Kenneth B. Margulies

5:20 PM
Panel Discussion

Moderators: Steven R. Houser
                   Peipei Ping

4:00 PM^*
Peptide Nanofibers for Protein Therapy: Some Assembly Required
Richard T. Lee

4:22 PM^*
In Situ, Tissue Engineering for Myocardial Repair
Randall J. Lee

4:44 PM^*
Tissue Engineering Hearts From Decellularized Scaffolds
Doris A. Taylor

5:08 PM^*
Periostin Promotes Cardiomyocyte Cell Re-Entry
Bernhard Kuhn

^* 20 minute presentation, 2-3 minute audience discussion

Chair: TBA

Moderators: Uri Elkayam
                   Marshall S. Stanton

8:30 AM
The Challenge of Heart Failure Hospitalizations: Clinical and Prognostic Implications
Uri Elkayam

8:42 AM
Right Ventricular Pressure Monitoring
Robert C. Bourge

8:54 AM
Left Atrial Pressure Monitoring
William T. Abraham

9:08 AM
Pulmonary Artery Pressure Monitoring
Philip B. Adamson

9:20 AM
Implantable Hemodynamic Monitoring Devices: FDA Point of View
Randall G. Brockman

9:35 AM
Panel Discussion

Moderators: Alan B. Miller
                   Clyde W. Yancy

8:30 AM
Left Ventricular Remodeling and Atrial Fibrillation
Alfred A. Bove

8:50 AM
Rate Control, Rhythm Control: What, When and How?
Brian Olshansky

9:10 AM
Advances in Imaging for Real Time Ablation Mapping
Timm-Michael L. Dickfeld

9:30 AM
A Practicum on Atrial Fibrillation: Who is the Right Patient?
Invited

9:50 AM
Panel Discussion

Moderators: Heather J. Ross
                   Lynne Warner Stevenson

8:30 AM
Defining Advanced Heart Failure by Prognostic Stratification
Douglas S. Lee

8:50 AM
Clinical Decision Trees in Advanced Heart Failure: Should We Implant VADs "Earlier"?
Randall C. Starling

9:10 AM
Clinical Decision Trees in Advanced Heart Failure: When to Transplant
Mariell L. Jessup

9:30 AM
Hope in the Hopeless Situation: Palliative Care
Sarah J. Goodlin

9:50 AM
Panel Discussion

Moderators: Mariann Piano
                   Susan J. Pressler

8:30 AM
Naturoceuticals and Heart Failure: Innocuous and Harmful?
Patricia A. Uber

8:50 AM
State of the Science in Diet and Cachexia
Lorraine S. Evangetista

9:10 AM
Sociocultural Factors Related to Ability to Follow a Low Sodium Diet
Donna J. Corley

9:30 AM
Effects of Dietary Fats on Inflammation
Terry A. Lennie

9:50 AM
Panel Discussion

Moderators: Mark P. Donahue
                   Kirk U. Knowlton

8:30 AM^*
CamK, Arrhythmias and Heart Failure
Mark E. Anderson

8:52 AM^*
Cardiac Regeneration in Zebrafish
Kenneth D. Poss

9:15 AM^*
Identifying Heart Failure Genes in Drosophila
Matthew J. Wolf

9:32 AM^*
Translating From Vertebrate Models of Heart Failure
Elizabeth M. McNally

^* 20 minute presentation, 2-3 minute audience discussion

Moderator: Mariell L. Jessup

Panelists:
J. Malcolm O. Arnold
Soon J. Park
J. Herbert Patterson
Heather J. Ross
William G. Stevenson
Suzanne J. Wingate

Moderators: Robert C. Bogaev
                   Michael B. Fowler

10:30 AM
When and How Should We Revascularize the Failing Ventricle?
Michael A. Acker

10:50 AM
Reconstructing the Ventricle: Are We Really There?
Nicholas G. Smedira

11:10 AM
New Ventricular Assist Devices
Bartley P. Griffith

11:30 AM
Percutaneous Cardiac Support Devices: What's Their Place?
Joseph G. Rogers

11:50 AM
Panel Discussion

Moderators: Paul A. Heidenreich
                   Adrian B. Van Bakel

10:30 AM
Assisting Severity of Mitral Valve Regurgitation in Heart Failure
Maurice E. Sarano

10:50 AM
Insights Into "Ischemic" Mitral Regurgitation
Robert C. Gorman

11:10 AM
Transcatheter Mitral Valve Therapy: Current Concepts
Peter C. Block

11:30 AM
Addressing the Aortic Valve in Heart Failure
Blase A. Carabello

11:50 AM
Panel Discussion

Moderators: Burns C. Blaxall
                   Gary S. Francis

10:30 AM^*
Role of ACE2 in Regulating RAS Activities
Thomas Coffmann

10:52 AM^*
Effects of Ang-(1-7) on Cardiac Structure and Function
Barry H. Greenberg

11:15 AM^*
The Mas Receptor
Thomas Walther

11:37 AM^*
The Renin Inhibitor Aliskren in Heart Failure
Bertram Pitt

^* 20 minute presentation, 2-3 minute audience discussion

Moderators: Ronglih Liao                                        Mark A. Sussman

10:30 AM^*
Cardiomyocyte Cell Cycle and Approaches for Cardiac Repair
Roberto Bolli

10:52 AM^*
Human ESC-Derived Cardiodmyocytes Enhance Function of the Infarcted Heart
Michael A. Laflamme

11:15 AM^*
Evidence of Myogenesis During Post-Natal Cardiac Growth
Steven R. Houser

11:37 AM^*
Molecular Signatures of Myogenic Stem Cells
Daniel J. Garry

^* 20 minute presentation, 2-3 minute audience discussion

7. The Cardiorenal Syndrome in Heart Failure
   Andrew J. Boyle, Maria Rosa Costanzo, Stephen S. Gottlieb



8. How to Manage the Outpatient Left Ventricular Assist Device
   Maureen P. Flattery, Leslie W. Miller, Marc A. Silver



9. Cardiac Resynchronization Therapy: How to Maximize Patient Outcomes
   Rebecca L. Angerstein, Christopher DeFilippi, Sanjiv M. Narayan



10. Are Heart Failure Registries Influencing Patient Care?
    Gregg C. Fonarow, J. Thomas Heywood, J. Herbert Patterson



11. Key Ingredients to a Successful Heart Failure Clinic
    Paul J. Mather, Sara C. Paul, Juanita Riegle



12. The Academic Nurse: Mentoring and Publishing
    Kathleen Dracup, Kathryn J. Hoercher, Linda Ohler, Barbara J. Riegel

Moderators: Inder S. Anand
                   Sidney Goldstein

12:30 PM^*
Human Myocardial b₁ 389 Arg/Arg Adrenergic Receptors Exhibit a Propensity for Constitutively Active, High Affinity Agonist Binding and are Selectively Inactivated by Bucindolol
Ryan Walsh

12:45 PM^*
Gene Variants in Caveolin-1 and Caveolin-2 in Patients with Idiopathic Pulmonary Arterial Hypertension
Christian Zellner

1:00 PM^*
Action Potential Dynamics Explain Arrhythmic Susceptibility in Systolic Heart Failure
Gautam G. Lalani

1:15 PM^*
The B-Type Natriuretic Peptide T-381C Polymorphism is Associated with Increased BNP Plasma Immunoreactivity and Higher Prevalence of Type 2 Diabetes Mellitus and Atrial Fibrillation
Lisa C. Costello-Boerrigter

^* 10 minute presentation, 5 minute audience discussion

Moderators: Carl V. Leier
                   Douglas D. Schocken

2:00 PM^*
The Concertina Pump
Ragavendra Baliga

2:15 PM^*
The Academic Paradigm is the Problem
Matthew Movsesian

2:30 PM^*
The End-Diastolic Pressure-Volume Relation: The Fool’s Gold of Diastolic Dysfunction
William Little

2:45 PM^*
Understanding a Misunderstanding: Getting It Wrong About Women and Heart Disease
Charles Porter

3:00 PM^*
It May Sound Ridiculous, but Insulin Resistance Actually Protects the Heart
Heinrich Taegtmeyer

3:15 PM^*
We’re All on Oxygen: Pet Peeves About Medical Communication
Phillip Binkley

^* 10 minute presentation, 5 minute audience discussion

Moderators: Jalal K. Ghali
                   John R. Teerlink

2:00 PM
What is "Diabetic Cardiomyopathy"
Thomas D. Giles

2:20 PM
Metabolic Modulation as a Treatment Target for Insulin Resistance Cardiomyopathy
Michael B. Fowler

2:40 PM
Antidiabetic Drugs and Heart Failure: Damned If You Do?
Prakash C. Deedwania

3:00 PM
Calcium Handling and Glycation Products in the Diabetic Heart
Wolfgang H. Dillmann

3:20 PM
Panel Discussion

Moderators: David S. Feldman
                   Yibin Wang

2:00 PM^*
Forkhead Transcription Factors and Cardiac Hypertrophy
Cam Patterson

2:22 PM^*
MicroRNAs: Novel Regulators of Cardiac Differentiation and Reaction to Injury
Deepak Srivastava

2:45 PM^*
Novel Roles of GSK-3 Family Members Defined on Isoform-Specific Knockouts
Thomas Force

3:07 PM^*
GATA4 Induced Angiogenesis
Jeffery Molkentin

^* 20 minute presentation, 2-3 minute audience discussion

Moderators: Mark E. Dunlap
                   Jonathan G. Howlett

DEBATE: The Heart Failure Continuum (Prevention to Destination) Is Best Managed in the USA

4:00 PM
Protagonist: Harlan M. Krumholz

4:15 PM
Antagonist: Paul W. Armstrong

4:30 PM
Rebuttal/Summary (7.5 minutes each)

DEBATE: An Endomyocardial Biopsy Should Be Performed in Most Heart Failure Patients

4:45 PM
Protagonist: James B. Young

5:00 PM
Antagonist: Stephen C. Gottlieb

5:15 PM
Rebuttal/Summary (7.5 minutes each)

Moderators: Stefan D. Anker
                   Hector O. Ventura

4:00 PM
Novel Cardiorenal Peptides
John C. Burnett

4:20 PM
Collagen Turnover in the Heart and Periphery
Wilson S. Colucci

4:40 PM
Oxidative Stress Biomarkers and Heart Failure
Joshua M. Hare

5:00 PM
Inflammatory Peptides: A Dead End?
Guillermo Torre-Amione

5:20 PM
Panel Discussion

Moderators: Srinivas Murali
                   Robert L. Scott

4:00 PM
Physiology and Function of the Right Ventricle: Mechanisms of Right Ventricle Failure
Hunter C. Champion

4:20 PM
Imaging the Right Ventricle: Cardiac MRI and Beyond
Fernando Torres

4:40 PM
Congenital Heart Disease and Pulmonary Hypertension: Managing Adults with Congestive Heart Faliure
Richard A. Krasuski

5:00 PM
Diastolic Heart Failure with RV Dysfunction and Pulmonary Hypertension: Sildenafil or All?
Myung H. Park

5:20 PM
Panel Discussion

Moderators: A. Martin Gerdes
                   Seigo Izumo

4:00 PM^*
Enteroviral Protease and Dilated Cardiomyopathy
Kirk U. Knowlton

4:22 PM^*
Bnip3 and Cardiomyocyte Apoptosis
Gerald W. Dorn

4:45 PM^*
ARC: An Inhibitor of Apoptosis
Richard A. Kitsis

5:07 PM^*
Adrenal Adrenoceptors in Heart Failure
Walter J. Koch

^* 20 minutes presentation, 2-3 minute audience discussion

Moderators: G. Michael Felker
                   Hani N. Sabbah

8:30 AM^*
TBA
TBA

8:48 AM^*
TBA
TBA

9:06 AM^*
TBA
TBA

9:24 AM^*
TBA
TBA

9:42 AM^*
TBA
TBA

^* 18 minutes allotted: 13 minute presentation, 5 minute audience discussion

Moderators: Kirkwood F. Adams
                   Charles L. Emerman

8:30 AM
Acute Heart Failure Syndromes: Intergrating the ED and Hospitalist Perspective
Alpesh N. Amin

8:50 AM
What Role Does the Cardiologist Play in the Management of AHFS?
Uri Elkayam

9:10 AM
The ED as an Inception Point for Clinical Trials in AHFS
Sean P. Collins

9:30 AM
Unmet Needs and Areas for Research and Collaboration
Mihai Gheorghiade

9:50 AM
Panel Discussion

Moderators: Arthur M. Feldman
                   Douglas H. Mann

8:30 AM
Genome-Wide Association Studies: Caveats and Promises
Robert Roberts

8:50 AM
The Genomics of Cardiomyopathy: A Paradigm for Cardiovascular Genetic Medicine
Ray E. Hershberger

9:10 AM
Insights From the "Transcriptome and Proteome" in Heart Failure
Peter P. Liu

9:30 AM
Genomic-Based Therapeutics: What Will It Take?
Michael R. Bristow

9:50 AM
Panel Discussion

Moderators: Kenneth Dickstein
                   Barry H. Greenberg

Heart Failure with Normal Ejection Fraction

8:30 AM
What Current and On-Going Trials Tell Us About This Population
Margaret R. Redfield

8:50 AM
Treatment of Heart Failure with Normal Ejection Fraction: "An Inconvenient Truth"
Walter J. Paulus

Statins in Heart Failure with Reduced Ejection Fraction

9:10 AM
Lessons From CORONA: The European Perspective
John C. Kjekshus

9:30 AM
What Did CORONA Really Tell Us: A US Viewpoint
Mandeep R. Mehra

9:50 AM
Panel Discussion

Moderators: Raymond L. Benza
                   Robert P. Frantz

10:30 AM
Pathogenesis of Pulmonary Arterial Hypertension: What Have We Learned?
Michael A. Mathier

10:50 AM
Screening and Diagnosis of PAH: Do We Really Need RHC
Teresa DeMarco

11:10 AM
The Available Therapeutic Armamentarium for PAH in 2008
Michael D. McGoon

11:30 AM
Emerging Therapeutic Options: Beyond Monotherapy
Vallerie V. McLaughlin

11:50 AM
Panel Discussion

Moderators: John B. O'Connell
                   David O. Taylor

10:30 AM
Viruses In and Around the Heart
Jeffery A. Towbin

10:50 AM
Clinical Pearls: How Should We "Screen" for Myocarditis?
Thomas G. DiSalvo

11:10 AM
Images Are Worth More Than Words: Noninvasive Diagnosis of Myocarditis
Jagat Narula

11:30 AM
Immunotherapy and Beyond
Patricia A. Uber

11:50 AM
Panel Discussion

Moderators: Kathleen A. Dracup
                   Donna M. Mancini

10:30 AM
Skeletal Muscle Physiology in Chronic Heart Failure
Barry M. Massie

10:50 AM
Molecular Signals That Trigger Physiologic Cardiac Growth
Anthony J. Muslin

11:10 AM
Enhancing Exercise Capacity in Heart Failure: Novel Strategies
Simon W. Maybaum

11:30 AM
What Have We Learned From ACTION-HF?
Ileana L. Piña

11:50 AM
Panel Discussion

Moderators: JoAnn Lindenfeld
                   Randall C. Starling

10:30 AM
Evaluation and Admission Criteria for Acute Heart Failure
WH Wilson Tang

Case: A 73 yr. old woman with chronic HF has a 12# weight gain, dyspnea, increasing edema, rales and recent increase in creatine and potassium. Should she be admitted?

10:50 AM
Update on Genetic Evaluation of Cardiomyopathy
Ray Hershberger

Case: A 46 yr. old man has new symptoms of mild HF. ECHO shows a mild global decrease sin EF and normal coronary arteries. Should you proceed with genetic testing?

11:10 AM
Heart Failure Patients Receiving Anti-Cancer Therapy: Updates and Issues of Evaluation
Daniel Lenihan

Case: A 65 yr. old woman with a new diagnosis of breast cancer is referred for evaluation prior to chemotherapy. 12 yrs. ago she had left chest irradiation for an unknown chest tumor. How should she be evaluated?

11:30 AM
Disease Management: New Factors to Consider
Debra K. Moser

Case: A patient has been diuresed and to be discharged in 48 hrs. She has a list of medications and when to call the office. She says she understands her discharge instructions. How to make certain she does understand and what are some factors to consider?

11:50 AM
Next Steps: New Areas for Guidelines?
JoAnn Lindenfeld